Severe Hypocalcemia Due to Skeletal Remineralization After Venetoclax, Bortezomib, and Dexamethasone for Relapsed Multiple Myeloma
Authors:
- Lydia InglezouLILydia Inglezou
- Giolanta TsekouGTGiolanta Tsekou
- Ioannis KotsianidisIKIoannis Kotsianidis
- Emmanouil SpanoudakisESEmmanouil Spanoudakis
- Konstantinos LiapisKLKonstantinos Liapis
- 3 January 2022
- journal article
- letter
- Published by SAGE Publications in Annals of Pharmacotherapy
- Vol. 56 (9) , 1076-1078
Abstract
No abstract availableThis publication has 9 references indexed in Scilit:
- Venetoclax or placebo in combination with bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma (BELLINI): a randomised, double-blind, multicentre, phase 3 trialThe Lancet Oncology, 2020
- The Bcl-2 specific BH3 mimetic ABT-199: a promising targeted therapy for t(11;14) multiple myelomaLeukemia, 2013
- ABT-737 is highly effective against molecular subgroups of multiple myelomaBlood, 2011
- ABT-737, an inhibitor of Bcl-2 family proteins, is a potent inducer of apoptosis in multiple myeloma cellsLeukemia, 2007
- Tumour lysis syndrome: new therapeutic strategies and classificationBritish Journal of Haematology, 2004
- CalciumThe Lancet, 1998
- Hungry bone syndrome: Clinical and biochemical predictors of its occurrence after parathyroid surgeryThe American Journal of Medicine, 1988
- A Hospital Survey of Hypocalcemia in Patients with Malignant DiseaseActa Medica Scandinavica, 1986
- A method for estimating the probability of adverse drug reactionsClinical Pharmacology & Therapeutics, 1981